Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia? Journal Article
| Authors: | Grimwade, D.; Tallman, M. S. |
| Article Title: | Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia? |
| Keywords: | cancer chemotherapy; cancer survival; cancer recurrence; salvage therapy; unspecified side effect; follow up; reverse transcription polymerase chain reaction; editorial; patient monitoring; health care cost; arsenic trioxide; minimal residual disease; promyelocytic leukemia; anthracycline; leukemia relapse; retinoic acid; quality adjusted life year; leukemia remission |
| Journal Title: | Leukemia Research |
| Volume: | 35 |
| Issue: | 1 |
| ISSN: | 0145-2126 |
| Publisher: | Elsevier Ltd |
| Date Published: | 2011-01-01 |
| Start Page: | 3 |
| End Page: | 7 |
| Language: | English |
| DOI: | 10.1016/j.leukres.2010.06.018 |
| PROVIDER: | scopus |
| PUBMED: | 20674017 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 4 March 2011" - "CODEN: LERED" - "Source: Scopus" |
